Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder

You may be eligible if

• Histologically confirmed post-transplant lymphoproliferative disorder (PTLD) of 1 of the following stages:
• * Stage III or IV
• * Localized (not amenable to localized radiotherapy or excision)
• * Recurrent
• The following histologies\* are eligible:
• * Polyclonal PTLD
• * Monoclonal PTLD
• * Diffuse large B-cell non-Hodgkin's lymphoma (NHL)
• * Lymphoplasmacytic NHL
• * Burkitt/Burkitt-like NHL
• Must not have completely responded during OR progressed after prior rituximab with or without chemotherapy
• * No history of rapid disease progression while receiving prior chemotherapy
• Measurable disease
• Must have less than 25% bone marrow involvement with lymphoma
• Prior solid organ transplantation required
• Evaluation of malignant cells for Epstein-Barr virus (EBV) required
• * EBV positive or negative allowed
• No pleural effusion
• No CNS lymphoma, including leptomeningeal disease
• No pulmonary involvement by NHL in patients with prior lung transplantation
• No HIV or AIDS-related lymphoma
• No hypocellular bone marrow (i.e., less than 15% cellularity)
• No marked reduction in bone marrow precursors of one or more cell lines (i.e., granulocytic, megakaryocytic, or erythroid)
• Performance status - Karnofsky 50-100%
• At least 3 months
• Absolute neutrophil count at least 1,500/mm\^3
• Platelet count at least 150,000/mm\^3
• Bilirubin no greater than 2.5 mg/dL
• Creatinine no greater than 2.5 mg/dL
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 6 months after study participation
• HIV negative
• No serious nonmalignant disease or infection that would compromise study objectives
• No presence of antimurine antibody reactivity
• No other concurrent active malignancy requiring therapy
• More than 2 weeks since prior filgrastim (G-CSF) or sargramostim (GM-CSF)
• More than 6 weeks since prior rituximab
• No prior allogeneic bone marrow or hematopoietic stem cell transplantation
• No prior radioimmunotherapy for NHL
• More than 4 weeks since prior chemotherapy
• See Biologic therapy
• No prior radiotherapy to more than 25% of active bone marrow (involved field or regional)
• More than 4 weeks since prior major surgery except diagnostic surgery
• No other concurrent anticancer therapy